Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease

被引：31

作者：

Altmann, Vivian ^{[1
]}

Schumacher-Schuh, Artur F. ^{[2
]}

Rieck, Mariana ^{[1
]}

Callegari-Jacques, Sidia M. ^{[3
]}

Rieder, Carlos R. M. ^{[2
]}

Hutz, Mara H. ^{[1
]}

机构：

[1] Univ Fed Rio Grande do Sul, Inst Biociencias, Dept Genet, BR-90049 Porto Alegre, RS, Brazil

[2] Hosp Clin Porto Alegre, Serv Neurol, Porto Alegre, RS, Brazil

[3] Univ Fed Rio Grande do Sul, Dept Estat, Porto Alegre, RS, Brazil

来源：

PHARMACOGENOMICS | 2016年 / 17卷 / 05期

关键词：

algorithm; dopamine transporter; levodopa; Parkinson's disease; pharmacogenetics; synaptic vesicle isoform C; DOPAMINE TRANSPORTER GENE; SYNAPTIC VESICLE PROTEIN; BODY-WEIGHT; SV2C; PHARMACOKINETICS; LOCALIZATION; EXPRESSION; DYSKINESIA; BRAIN;

D O I：

10.2217/pgs.15.183

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aim: Levodopa is first-line treatment of Parkinson's disease motor symptoms but, dose response is highly variable. Therefore, the aim of this study was to determine how much levodopa dose could be explained by biological, pharmacological and genetic factors. Patients & methods: A total of 224 Parkinson's disease patients were genotyped for SV2C and SLC6A3 polymorphisms by allelic discrimination assays. Comedication, demographic and clinical data were also assessed. Results: All variables with p < 0.20 were included in a multiple regression analysis for dose prediction. The final model explained 23% of dose variation (F = 11.54; p < 0.000001). Conclusion: Although a good prediction model was obtained, it still needs to be tested in an independent sample to be validated.

引用

页码：481 / 488

页数：8

共 50 条

[41] Genetic risk factors in Parkinson's disease
Billingsley, K. J.
Bandres-Ciga, S.
Saez-Atienzar, S.
Singleton, A. B.
CELL AND TISSUE RESEARCH, 2018, 373 (01) : 9 - 20
[42] Genetic risk factors in Parkinson's disease
Tsang, KL
Feng, ZH
Jiang, H
Ramsden, DB
Ho, SL
MAPPING THE PROGRESS OF ALZHEIMER'S AND PARKINSON'S DISEASE, 2002, 51 : 251 - 257
[43] Genetic and environmental factors of Parkinson's disease
Broussolle, E
Thobois, S
REVUE NEUROLOGIQUE, 2002, 158 : S11 - S23
[44] Genetic risk factors in Parkinson's disease
Wood, NW
ANNALS OF NEUROLOGY, 1998, 44 (03) : S58 - S62
[45] Genetic factors in the etiology of Parkinson's disease
Gershanik, O.
PARKINSONISM & RELATED DISORDERS, 2009, 15 : S27 - S27
[46] Genetic risk factors in Parkinson’s disease
K. J. Billingsley
S. Bandres-Ciga
S. Saez-Atienzar
A. B. Singleton
Cell and Tissue Research, 2018, 373 : 9 - 20
[47] Testing for genetic factors in Parkinson's disease
Conneally, PM
MOVEMENT DISORDERS, 2006, 21 : S27 - S27
[48] Levodopa and the progression of Parkinson's disease
Fahn, S
Shoulson, I
Kieburtz, K
Rudolph, A
Lang, A
Olanow, CW
Tanner, C
Marek, K
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24): : 2498 - 2508
[49] The study of genetic factors in motor levodopa-induced complications development in Russian patients with Parkinson's disease
Akhmadeeva, G.
Khidiyatova, I.
Gilyazova, I.
Tayupova, G.
Umutbaev, S.
Baitimerov, A.
Magzhanov, R.
MOVEMENT DISORDERS, 2021, 36 : S304 - S304
[50] The study of genetic factors in levodopa-induced motor complications development in Russian patients with Parkinson's disease
Akhmadeeva, G.
Khidiyatova, I.
Gilyazova, I.
Umutbaev, S.
Galimova, R.
Baitimerov, A.
Magzhanov, R.
MOVEMENT DISORDERS, 2023, 38 : S466 - S466

← 1 2 3 4 5 →